The AAPS Journal

, 21:9 | Cite as

Measurement of IL-17AA and IL-17FF as Pharmacodynamic Biomarkers to Demonstrate Target Engagement in the Phase I Study of MCAF5352A

  • Kun PengEmail author
  • Yehong Wang
  • Ketevan Siradze
  • Rich Erickson
  • Saloumeh K. Fischer
  • Tracy L. Staton
Research Article


The interleukin (IL)-17 pathway has been implicated in the pathophysiology of many autoimmune diseases. MCAF5352A is a humanized monoclonal antibody which targets both IL-17A and IL-17F, thereby inhibiting the activity of IL-17 dimers (IL-17AA, IL-17AF, and IL-17FF). The pharmacokinetic profile of MCAF5352A has been characterized in both a Phase Ia single ascending dose study and a Phase Ib multiple ascending dose study. Two qualified enzyme-linked immunosorbent assays were used to measure total IL-17AA and IL-17FF levels in serum as pharmacodynamic biomarkers in the Phase I studies. The two assays demonstrated specificity for IL-17AA or IL-17FF with sensitivity at low picogram/milliliter levels. The assay precision and accuracy also met acceptance criteria. Although total serum IL-17AA and IL-17FF levels were below the assay detection limits prior to administration of MCAF5352A, post-treatment levels in both the single and multiple dose cohorts became detectable and increased in a dose-dependent manner. These data are consistent with target engagement by MCAF5352A. Our work highlights bioanalytical challenges encountered while developing biomarker assays requiring high sensitivity and specificity. Data generated using these assays enabled the confirmation of target engagement during early clinical drug development.


anti-IL-17 monoclonal antibody biomarker assay IL-17AA IL-17FF pharmacodynamics 



MCAF5352A is a molecule in-licensed from Novimmune SA.

Funding Details

This study was funded by Genentech Inc., South San Francisco, CA, USA.

Compliance with Ethical Standards

Conflict of Interest

All authors are Genentech employees and Roche shareholders.


  1. 1.
    Weaver CT, Murphy KM. The central role of the Th17 lineage in regulating the inflammatory/autoimmune axis. Semin Immunol. 2007;19(6):351–2. Scholar
  2. 2.
    Kang Z, Wang C, Zepp J, Wu L, Sun K, Zhao J, et al. Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells. Nat Neurosci. 2013;16(10):1401–8. Scholar
  3. 3.
    Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity. 2008;28(4):454–67. Scholar
  4. 4.
    Hashimoto T, Akiyama K, Kobayashi N, Mori A. Comparison of IL-17 production by helper T cells among atopic and nonatopic asthmatics and control subjects. Int Arch Allergy Immunol. 2005;137(Suppl 1):51–4. CrossRefPubMedGoogle Scholar
  5. 5.
    Linden A, Hoshino H, Laan M. Airway neutrophils and interleukin-17. Eur Respir J. 2000;15(5):973–7.CrossRefGoogle Scholar
  6. 6.
    Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5(2):101–4. Scholar
  7. 7.
    Wong ET, Joseph JT. Meningeal carcinomatosis in lung cancer. Case 1. Carcinomatous leptomeningeal metastases. J Clin Oncol. 2000;18(15):2926–7. CrossRefPubMedGoogle Scholar
  8. 8.
    Gordon KB, Blauvelt A, Papp KA, Langley RG, Luger T, Ohtsuki M, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–56. Scholar
  9. 9.
    Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38. Scholar
  10. 10.
    Mease PJ, van der Heijde D, Ritchlin CT, Okada M, Cuchacovich RS, Shuler CL, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76(1):79–87. Scholar
  11. 11.
    Blanco FJ, Moricke R, Dokoupilova E, Codding C, Neal J, Andersson M, et al. Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator- and placebo-controlled study. Arthritis Rheumatol. 2017;69(6):1144–53. Scholar
  12. 12.
    McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46. Scholar
  13. 13.
    Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273–86. Scholar
  14. 14.
    Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm. 2005;2005(5):273–9. Scholar
  15. 15.
    Balasa R, Bajko Z, Hutanu A. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Mult Scler. 2013;19(7):885–90. CrossRefPubMedGoogle Scholar
  16. 16.
    Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-alpha therapy. Arthritis Res Ther. 2011;13(4):R126. Scholar
  17. 17.
    Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, et al. Interleukin 17F level and interferon beta response in patients with multiple sclerosis. JAMA Neurol. 2013;70(8):1017–21. Scholar
  18. 18.
    Lei Z, Liu G, Huang Q, Lv M, Zu R, Zhang GM, et al. SCF and IL-31 rather than IL-17 and BAFF are potential indicators in patients with allergic asthma. Allergy. 2008;63(3):327–32. CrossRefPubMedGoogle Scholar
  19. 19.
    Ramos-Cejudo J, Oreja-Guevara C, Stark Aroeira L, Rodriguez de Antonio L, Chamorro B, Diez-Tejedor E. Treatment with natalizumab in relapsing-remitting multiple sclerosis patients induces changes in inflammatory mechanism. J Clin Immunol. 2011;31(4):623–31. Scholar
  20. 20.
    Schofield C, Fischer SK, Townsend MJ, Mosesova S, Peng K, Setiadi AF, et al. Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis. Bioanalysis. 2016;8(22):2317–27. Scholar
  21. 21.
    FDA Bioanalytical Method Validation Guidance for Industry. 2018.
  22. 22.
    Peng K, Siradze K, Quarmby V, Fischer SK. Clinical immunogenicity specificity assessments: a platform evaluation. J Pharm Biomed Anal. 2011;54(3):629–35. Scholar
  23. 23.
    Hochhaus G, Brookman L, Fox H, Johnson C, Matthews J, Ren S, et al. Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma. Curr Med Res Opin. 2003;19(6):491–8. Scholar
  24. 24.
    Lachmann HJ, Lowe P, Felix SD, Rordorf C, Leslie K, Madhoo S, et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med. 2009;206(5):1029–36. Scholar
  25. 25.
    Cai F, Hornauer H, Peng K, Schofield CA, Scheerens H, Morimoto AM. Bioanalytical challenges and improved detection of circulating levels of IL-13. Bioanalysis. 2016;8(4):323–32. Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Kun Peng
    • 1
    Email author
  • Yehong Wang
    • 2
  • Ketevan Siradze
    • 1
  • Rich Erickson
    • 1
  • Saloumeh K. Fischer
    • 1
  • Tracy L. Staton
    • 3
  1. 1.Department of BioAnalytical SciencesGenentech IncSouth San FranciscoUSA
  2. 2.Department of Clinical PharmacologyGenentech IncSouth San FranciscoUSA
  3. 3.Department of OMNI Biomarker DevelopmentGenentech IncSouth San FranciscoUSA

Personalised recommendations